Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PopVax influenza vaccine
- Development stage
- Approved
- Lead developer
- PopVax
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Transdermal
01
Overview
PopVax is developing an mRNA-encoded virus-like particle (VLP) vaccine for the prevention of seasonal and pandemic influenza. The vaccine utilizes a proprietary mRNA architecture designed for immunogen display, delivered via a lipid nanoparticle (LNP) platform. Unlike traditional mRNA vaccines that encode soluble antigens, this technology directs cells to produce antigens that self-assemble into VLPs, which mimic the structural characteristics of the native influenza virus to elicit a more potent immune response. Preclinical studies in mice have demonstrated antibody responses up to 250-fold greater than those of currently approved vaccines, as well as cross-protective immunity against pandemic strains such as H5N1. The program is currently in late preclinical development, with a patch-delivered version also being advanced through funding from BARDA.
- Other names
- mRNA-encoded VLP influenza vaccinePopVax mRNA influenza vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on PopVax influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PopVax influenza vaccine.